Varian Medical Systems, Inc. (NYSE:VAR) Seals A New Deal For Its ProBeam Compact Proton Therapy

0
Varian Medical Systems, Inc. (NYSE:VAR) Seals A New Deal For Its ProBeam Compact Proton Therapy

Through its distributor, Business Alignment, Varian Medical Systems, Inc. (NYSE:VAR) has obtained a new deal with the oncology center at King Chulalongkorn Memorial Hospital in Bangkok. The manufacturer of medical devices and software will supply and install at the center its Varian ProBeam Compact single-room proton therapy system.

This is another big milestone for the company, which has been focusing a lot of its energy on saving lives. Apart from supplying the equipment, the company will provide another two types of equipment; Eclipse treatment planning and ARIA® information management systems.

The full-featured ProBeam Compact is comprehensive

The Varian ProBeam Compact system is a fully rotational intensity modulated proton therapy (IMPT) with an all-inclusive suite of motion management tools. It also has robotic patient positioning tools. Dr. Chonlakiet Khorprasert of King Chulalongkorn Memorial Hospital says that these are some of the many reasons for endorsing it alongside the company’s history of innovation in cancer treatment and the technical advances in the system.

On the other hand, the GM of Varian’s Particle Therapy division, Dr. Moataz Karmalawy cites, “By giving our Compact system all the technical capabilities, clinics around the world are realizing they can install an advanced system that can deliver high-quality care without compromise.”

Varian has been gaining prominence on its strategic initiatives

The manufacturer has been swift with its strategic initiatives with the significant addition of the ProBeam platform. It will come in handy in the treatment of cancer in Thailand. The company is projecting to place an order for the equipment by the third quarter of fiscal 2017 and then have it on board for use by the second half of 2019.

Varian has been enjoying a pleasant presence in the niche markets of Asia as a result of Shonin’s approval in Japan. Besides, there is a lot of optimism about the Asia proton therapy market, which is expected to at a CAGR of 18%. Nonetheless, it will have to go an extra mile to sustain competition from the bigwigs the likes of Hitachi. Meanwhile, Varian closed at $100.62 witnessing an increase of $1.60 or 1.62% per share.